Posted by Michael Wonder on 06 Jul 2017
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
6 July 2017 - Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx versus Stelara in psoriasis.
Novartis announced today that the CHMP has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis. The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis.
The updated label also includes use of Cosentyx to treat moderate-to-severe scalp psoriasis - one of the most difficult-to-treat forms of psoriasis, which affects approximately 60 million people worldwide. The updated label is based on the proven efficacy and consistent safety profile of Cosentyx.
